SCHEMBL1104409

SCHEMBL1104409

Cc1cccc2c1Nc1c(-c3ccccc3-c3nnc(N)o3)nc3ccc(F)c-2n13

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 5/20 0.35
PIM3 Q86V86 5/20 0.35
PIM2 Q9P1W9 5/20 0.35
SMN1; SMN2 Q16637 3/20 0.33
MAPT P10636 3/20 0.33
TP53 P04637 1/20 0.33
NPC1 O15118 2/20 0.32
CASP3 P42574 2/20 0.32
RAB9A P51151 2/20 0.32
SENP8 Q96LD8 2/20 0.32
SENP7 Q9BQF6 2/20 0.32
SENP6 Q9GZR1 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.31
KDM4E B2RXH2 2/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
KMT2A Q03164 1/20 0.31
HSD17B10 Q99714 1/20 0.31
HPGD P15428 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1104563 0.87 ALOX15 (0.41) SMN1; SMN2MAPTTP53NPC1CASP3
SCHEMBL1103965 0.78 GAA (0.41) SMN1; SMN2MAPTTP53NPC1RAB9A
SCHEMBL1104467 0.69 PTGER3 (0.34)
SCHEMBL1087234 0.67 GAA (0.46) SMN1; SMN2MAPTTP53L3MBTL1KDM4E
SCHEMBL13170400 0.65 RAB9A (0.74) SMN1; SMN2MAPTTP53NPC1CASP3
SCHEMBL16848496 0.65 RAB9A (0.50) PIM1PIM3PIM2SMN1; SMN2MAPT
SCHEMBL20547168 0.62 NOTUM (0.55) PIM1PIM3PIM2NPC1RAB9A
SCHEMBL1104524 0.58 NR1H4 (0.44) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL1531775 0.57 ALOX15 (0.59) SMN1; SMN2MAPTTP53NPC1RAB9A
SCHEMBL21524800 0.57 L3MBTL1 (0.48) SMN1; SMN2TP53NPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153649-B2 3-aminoimidazo 1,2-A pyridine derivatives having an SGLT1- and SGLT2-inhibiting action for the treatment of type 1 and type 2 diabetes MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-04-10 US disclosed
US-20100305142-A1 3-AMINOIMIDAZO 1,2-A PYRIDINE DERIVATIVES HAVING AN SGLT1- AND SGLT2-INHIBITING ACTION FOR THE TREATMENT OF TYPE 1 AND TYPE 2 DIABETES MERCK PATENT GESELLSCHAFT (DE) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305142-A1 3-AMINOIMIDAZO 1,2-A PYRIDINE DERIVATIVES HAVING AN SGLT1- AND SGLT2-INHIBITING ACTION FOR THE TREATMENT OF TYPE 1 AND TYPE 2 DIABETES SLC5A1, SLC5A2, GLP1R PIM1 948/4885PIM3 1315/4885PIM2 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.